GlobeNewswire

Clariant AG: Clariant signs an agreement regarding the sale of its Healthcare Packaging Business

Share
  • Divestment of Clariant’s Healthcare Packaging Business to Arsenal Capital Partners
  • Total consideration of approx. CHF 308 million
 
 

Muttenz, July 22, 2019 - Clariant, a focused and innovative specialty chemical company, has signed an agreement with respect to the sale of its Healthcare Packaging business to a newly-formed affiliate of Arsenal Capital Partners. The total consideration of the sale amounts to approximately CHF 308 million payable at closing, which is expected in Q4 2019. The total consideration is equivalent to 13.2 times adjusted FY2018 EBITDA. The closing of the transaction is subject to customary conditions and approvals.

Clariant’s Healthcare Packaging business offers products used to protect pharmaceutical products from moisture and oxygen.  This includes customizable, high-quality drop-in products (canisters and packets), Integrated Desiccant Systems and specially designed plastic bottles containing oxygen barrier materials. In 2018, the Healthcare Packaging business generated sales of around CHF 135 million. The business has manufacturing facilities in the USA, France, China and India and employs around 600 employees.

CORPORATE MEDIA RELATIONS INVESTOR RELATIONS
 

Jochen Dubiel

Phone +41 61 469 63 63
jochen.dubiel@clariant.com
Anja Pomrehn

Phone +41 61 469 67 45
anja.pomrehn@clariant.com
Claudia Kamensky

Phone +41 61 469 63 63
claudia.kamensky@clariant.com
Maria Ivek

Phone +41 61 469 63 73
maria.ivek@clariant.com
Thijs Bouwens

Phone +41 61 469 63 63
Thijs.bouwens@clariant.com
 
Follow us on Twitter, Facebook, Google Plus, LinkedIn.  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.

 

 

www.clariant.com

 

 

Clariant is a focused and innovative specialty chemical company, based in Muttenz near Basel/Switzerland. On 31 December 2018 the company employed a total workforce of 17 901. In the financial year 2018, Clariant recorded sales of CHF 6.623 billion for its continuing businesses. The company reports in four business areas: Care Chemicals, Catalysis, Natural Resources, and Plastics & Coatings. Clariant’s corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.


Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Orion publishes Financial Statement Release for 2019 on 5 February 202022.1.2020 08:00:00 CETPress release

ORION CORPORATION PRESS RELEASE 22 JANUARY 2019 at 09.00 EET Orion will publish its Financial Statement Release for 2019 on Wednesday, 5 February 2020 approximately at 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. News conference A news conference and a conference call for analysts, investors and media will be held on Wednesday, 5 January 2020 at 13.30 EET at Orion's head office, address Orionintie 1A, Espoo. Participants are requested to present a photo ID at the head office reception. A link to the live webcast will be available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day. To participate the conference call, please dial: Finland: +358 9 817 103 10 Sweden: +46 8 566 426 51 UK: +44 33 3300 0804 USA: +1 855 857 0686 PIN: 45651029# Silent period The silent period preceding the publication is ongoing and

Prosafe SE: Q4 2019 results and webcast on 6 February 202022.1.2020 07:30:00 CETPress release

Prosafe SE will release its fourth quarter 2019 results on 6 February 2020 at approx. 07:00 a.m. CET. Jesper Kragh Andresen, CEO and Stig H. Christiansen, Deputy CEO & CFO will the same day at 10:00 a.m. CET present the results at Felix Konferansesenter, Bryggetorget 3, Oslo. The presentation can be followed live via web streaming at www.prosafe.com. It will be possible to ask questions during the presentation by using the Q&A tool embedded in the webcast. The webcast will be available for replay at www.prosafe.com Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 22 January 2020 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosur

Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer22.1.2020 07:15:00 CETPress release

Extension of existing agreement with Roche for supply of PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) Basel, Switzerland, January 22, 2020 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it extended its clinical supply agreement (CSA) with Roche (SIX: RO, ROG) to explore a combination of Basilea’s panFGFR kinase inhibitor derazantinib and Roche’s atezolizumab (Tecentriq®)1 in patients with gastric (stomach) cancer. The initial CSA covered urothelial (bladder) cancer and was concluded in January 2019. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study (FIDES-03) in advanced gastric cancer patients with FGFR genetic aberrations in the third quarter of 2020. The study will assess the efficacy and safety of derazantinib as mono- and combination therapy in the second-line setting. Basilea will be the sponsor of the study and Roche will provide clinical supply of atezolizumab, a PD-L1 checkpoint inhibitor. Dr. Marc Engelhardt, Chief Medical Officer

Millicom’s subsidiary Telefónica Celular del Paraguay S.A.E. announces the pricing of a US$250 million re-tap to its 5.875% Senior Notes due 2027.22.1.2020 00:32:00 CETPress release

Millicom’s subsidiary Telefónica Celular del Paraguay S.A.E. announces the pricing of a US$250 million re-tap to its 5.875% Senior Notes due 2027. Luxembourg, January 22, 2020 – Millicom’s wholly-owned subsidiary Telefónica Celular del Paraguay S.A.E, (“the “Company”) announced the pricing of a US$250 million re-tap to its senior unsecured notes due 2027 (“New Notes”), representing an additional issuance of the Company’s outstanding US$300 million 5.875% Senior Notes due 2027 issued on April 5, 2019 (the “Initial Notes”). The New Notes will be treated as a single class with the Initial Notes, and they were priced at 106.375 for an implied yield to maturity of 4.817%. The offering is expected to close on January 28, 2020. The Company intends to use the net proceeds from the offering to repay certain local borrowings, and for general corporate purposes, which could include, in addition to funding operations, distributions to shareholders. The New Notes are being offered only to qualified

Medtronic Named to FORTUNE’s 2020 World’s Most Admired Companies List21.1.2020 16:57:00 CETPress release

Global Leader in Medical Technology Ranks #2 in Industry on Annual List DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) has been named to FORTUNE’s 2020 World’s Most Admired Companies List. The global leader in medical technology landed at #2 in the Medical Products and Equipment industry. “We are honored to be selected by Fortune for this prestigious recognition,” said Omar Ishrak, Medtronic chairman and chief executive officer. “Our 90,000 people around the world strive every day to bring innovative products to market that achieve our longstanding Mission - to alleviate pain, restore health, and extend life. We seek to achieve this Mission responsibly, and we remain committed to being a company worthy of the trust and admiration of our investors, employees and customers.” The annual list measures corporate reputation among the world’s largest companies – the 1,000 largest U.S. companies by revenue, along with non-U.S. companies in Fortune’s Global 500 database that

The Private Placement of Secured Notes of AS PRFoods and the Results of the Placement21.1.2020 16:17:00 CETPress release

The Private Placement of Secured Notes of AS PRFoods and the Results of the Placement THIS NOTICE IS NOT INTENDED FOR PUBLICATION, ALLOCATION OR TRANSMISSION, IN PART OR WHOLLY, DIRECTLY OR INDIRECT, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR WHERE THE DISCLOSURE OR TRANSMISSION OF THIS INFORMATION IS NOT ALLOWED. By a company announcement dated 19 December 2020, AS PRFoods (hereinafter "PRFoods") informed investors that it was planning an issue of notes. PRFoods hereby notifies that the supervisory board of PRFoods has approved the principal terms and conditions of the note issue and has authorised the management board to issue up to 100,000 secured notes, with the maximum aggregate nominal value of up to EUR 10,000,000, nominal value of EUR 100 per note, interest rate of 6.25% per annum and maturity date on 22 January 2025 (hereinafter the “Notes”). Other than as brought out above, the material terms and conditions of the Notes